


# Allendale Biosciences

**CRISIL Rating: SME 3**

'Good'

Indicates the level of creditworthiness, adjudged in relation to other SMEs

Report Date: September 11, 2018 / Valid Till: September 10, 2019



## Important notice

The rating is a one-time exercise and the rating will not be kept under surveillance. This rating is valid for one year from the report date, subject to no significant changes/events occurring during this period that could materially affect the business or financial parameters of the organisation as mentioned in the report. CRISIL, however, recommends that the user of the rating seeks a review of the rating if the organisation experiences significant changes/events during this period which could impact the organisation/its rating.

The rating and this report are based on the information provided to CRISIL by the organisation and/or obtained by CRISIL from sources it considers reliable including published annual reports, management meetings, industry data and discussions with bankers, customers and suppliers. CRISIL does not guarantee the accuracy, adequacy or completeness of any information on which the rating and the report are based and is not responsible for any errors or omissions for the results/opinions obtained from the use of the rating or the rating report. The rating does not constitute an audit of the organisation by CRISIL. The rating is also not a recommendation to enter into or not enter into any transaction with the organisation. CRISIL reserves the right to disclose the organisation's rating and the rating report to Government and/or Regulatory Authorities/Courts of Law if required to do so.

It is especially stated that CRISIL, its Directors, Rating Committee members, employees and others associated with the rating assignment do not have any financial liability whatsoever including but not limited to attorney's or consultant's fees to the users of this rating or this rating report. No part of this report may be reproduced by any means without CRISIL's prior written approval.

## Index

<b>CRISIL SME rating</b> .....	<b>2</b>
<b>Key rating drivers</b> .....	<b>3</b>
Business and management.....	3
Financial .....	3
<b>Fact sheet</b> .....	<b>4</b>
<b>Business profile</b> .....	<b>5</b>
Business description .....	5
Product profile .....	7
Customer profile and demand-side analysis.....	7
Supplier profile and supply-side analysis .....	7
Trading facilities .....	8
<b>Ownership and management</b> .....	<b>9</b>
Partners' profile .....	9
Key management personnel .....	10
Organisational structure, controls and systems .....	10
Ownership pattern .....	11
Group companies and firms .....	11
<b>Financial profile</b> .....	<b>12</b>
Current financial performance.....	12
Past financial performance.....	13
Profit and loss account .....	13
Balance sheet .....	14
Key financial ratios.....	15
Fund flow statement .....	16
Graphs .....	17
Banking facilities .....	18
<b>Site visit</b> .....	<b>19</b>

## CRISIL SME rating

<b>SME 3</b> indicates 'Good' creditworthiness in relation to other SMEs	CRISIL SME Rating	Definition
	SME 1	Highest
	SME 2	High
	<b>SME 3</b>	<b>Good</b>
	SME 4	Above Average
	SME 5	Average
	SME 6	Below Average
	SME 7	Weak
	SME 8	Poor

## Key rating drivers

### Business and management

<b>Strengths</b>	<ul style="list-style-type: none"> <li>• <b>Established track record and partner's extensive experience in the pharmaceuticals industry:</b> The firm has an experience of 7 years and the partners have an experience of around 3 decades in the pharmaceuticals industry that lends stability to the firm's business risk profile. The firm derives significant benefits from the strong reputation of its partners.</li> <li>• <b>Certification:</b> The firm has an ISO-9001:2015 quality certification, which ensures adherence to high quality standards and also enhances its brand value and demand prospects.</li> <li>• <b>Wide product range:</b> The firm has a well-diversified base of end-users as it offers 235 types of pharmaceutical drugs in the form of tablets, capsules, syrups, protein powder, etc.</li> <li>• <b>Wide geographical presence:</b> The firm is likely to benefit by a wide geographical presence with recognised brands in the pharmaceuticals industry across several states through its franchise model business. It also mitigates the risk of geographic concentration.</li> <li>• <b>Healthy growth in the domestic market:</b> The rising incidence of chronic ailments will drive growth in the urban areas, while demand for acute therapies will remain strong in the rural areas. Also, factors, such as rising healthcare awareness, insurance and per capita income, will drive demand in the domestic formulations market.</li> </ul>
<b>Risk factors</b>	<ul style="list-style-type: none"> <li>• <b>Regulatory risk:</b> The pharmaceutical/drugs industry operates within the regulatory framework laid down by the market for safeguarding quality, intellectual property, and maintaining drug efficacy. Any adverse regulatory action would impact the profitability and revenues of players.</li> <li>• <b>Factors that may constrain margin in the future:</b> <ul style="list-style-type: none"> <li>○ Volatility in the price of traded goods</li> <li>○ Intense competition from new and established players</li> </ul> </li> </ul>

### Financial

<b>Strengths</b>	<ul style="list-style-type: none"> <li>• <b>Strong capital structure:</b> The firm's debt-equity ratio (considering promoter loans as neither debt nor equity) was 0.01 time and TOL/TNW is 1.95 times as of fiscal 2017. CRISIL expects that the capital structure will remain adequate in the near term in absence of any major capital expenditure.</li> <li>• <b>Adequate interest coverage:</b> The firm has an adequate interest coverage as reflected in profit before depreciation, interest, and tax (PBDIT) interest cover of more than 40.00 times over the last 3 years ended fiscal 2017.</li> <li>• <b>Adequate liquidity:</b> The firm has adequate cash to meet its debt obligations as reflected in cash/TOL ratio of 4.72% and current ratio of 2.07 times as of fiscal 2017.</li> </ul>
<b>Risk factors</b>	<ul style="list-style-type: none"> <li>• <b>Moderate profitability:</b> The firm's ability to maintain operational efficiency while scaling up remains to be seen, as its operating profit before depreciation, interest, and tax (OPBDIT) margin declined to 3.25% in fiscal 2017 from 3.94% in fiscal 2016, PAT margin declined to 3.09% in fiscal 2017 from 3.84% in fiscal 2016, and return on capital employed (RoCE) declined to 10.70% in fiscal 2017 from 13.96% in fiscal 2016.</li> <li>• <b>Working capital management:</b> The firm's receivables were stretched in past 3 years due to weak bargaining power, and its payables were also stretched in past 3 years. The organisation's ability to strengthen its working capital management thus remains to be seen.</li> <li>• <b>Low NCA/TD:</b> This is reflected in the firm's net cash accruals/total debt, which declined to 1.54% in fiscal 2017 from 85.26% in fiscal 2016.</li> </ul>

## Fact sheet

<b>Name of the firm</b>	Allendale Biosciences
<b>Year of establishment and commencement of operations</b>	2011
<b>Legal status</b>	Partnership
<b>Legal history</b>	<ul style="list-style-type: none"> <li>• <b>2011:</b> Established as a partnership with Arvind Kumar Sharma and Neeraj Giri as partners</li> <li>• Since then, there has been no change in the firm's name, business, management, and constitution.</li> </ul>
<b>Registered with</b>	Registrar with Firms, Haryana
<b>Registration number</b>	06AAUF4651KZ2
<b>SSI registration number</b>	Data sought by CRISIL, not provided by firm
<b>Udhyog aadhaar no</b>	
<b>Managing partner</b>	Arvind Kumar Sharma
<b>Category of entrepreneur</b>	General
<b>Registered office, administrative office and trading facilities</b>	Plot No. 363, 2nd Floor Industrial Area, Phase 2 Panchkula – 134 113, Haryana Tel: +91 8570 052 000 +91 7696 513 118 Email: <a href="mailto:allendalebiosci@gmail.com">allendalebiosci@gmail.com</a> Website: <a href="http://www.allendalebiosciences.com">www.allendalebiosciences.com</a>
<b>Number of employees</b>	Permanent: 9 Contractual: Nil <b>Total: 9</b>
<b>Certifications and awards</b>	ISO 9001:2015 (validity November 10, 2020)
<b>Brands</b>	Airpure
<b>Statutory compliance</b>	<ul style="list-style-type: none"> <li>• Income tax filing: Regular and timely</li> <li>• Excise duty filing (till June 30, 2017): Not applicable (trading business)</li> <li>• Sales tax filing (till June 30, 2017): Regular and timely</li> <li>• GST filing (since July 1, 2017): Regular and timely</li> <li>• Wealth tax filing: Regular and timely</li> <li>• ESIC and EPF dues: Not applicable (less than 20 employees)</li> </ul> <i>(As provided by the management, not independently verified)</i>

## Business profile

### Business description

Nature of business	:	Trading
Industry	:	Pharmaceuticals - Bulk Drugs
Industry prospects	:	Strong
Business description	:	<ul style="list-style-type: none"> <li>• <b>Business:</b> The firm trades in 235 types of pharmaceutical drugs.</li> <li>• <b>Products:</b> <ul style="list-style-type: none"> <li>○ Tablets</li> <li>○ Capsules</li> <li>○ Syrups</li> <li>○ Sachets</li> <li>○ Gels</li> <li>○ Protein Powders</li> </ul> </li> <li>• <b>Expiry:</b> Most of the pharmaceutical drugs have an expiry period from 18 month to 3 years.</li> <li>• <b>Margin:</b> The firm maintains gross margin of 25.00% to 30.00%.</li> <li>• <b>Franchise:</b> The firm runs its operation through franchise business and Pharma PCD.</li> <li>• <b>Monopoly right:</b> The firm provides monopoly rights to its franchise, where the franchise needs to make a minimum order of Rs 0.30 lakh to Rs 5.00 lakh for taking franchise. There is no franchise fee for franchisee. The whole process runs on written agreement.</li> <li>• <b>Inventory holding:</b> The firm maintains an inventory of traded goods for 45 days to 60 days.</li> <li>• <b>Warehouse:</b> The firm has a warehouse in the trading facility itself to stock the traded goods and also a cold storage facility like refrigerator to keep some pharmaceutical drugs.</li> <li>• <b>Logistics:</b> The firm has local tie-up for transportation facility and cost of the same is borne by the customer.</li> <li>• <b>Shift:</b> The firm operates in a single shift of 8 hours.</li> </ul>
End-user industries	:	Diverse
Experience in the business	:	7 years
Product range	:	Diversified
Degree of competition	:	High; entry barriers are low

<b>Plans</b>	:	<ul style="list-style-type: none"> <li>• <b>FY19:</b> The firm has started a new division Cardio Diabetic with the help of Voizmed Pharma. The firm has also requested for enhancement in bank overdraft facility.</li> <li>• <b>FY20:</b> The firm plans to venture into the infertility drugs segment.</li> </ul>
<b>Customer profile</b>	:	Direct and Institutional customers
<b>Installed capacity/facility</b>	:	Not applicable
<b>Utilised capacity</b>	:	



## Product profile

Product profile	Share in net sales (%)
Pharmaceuticals drugs	100.00
<b>Total</b>	<b>100.00</b>

## Customer profile and demand-side analysis

Customer name	Address	Product	Length of relationship	% share in sales
Medicinum	Chhattisgarh	Pharmaceuticals drugs	5 years	25.00
Classic Pharma	Punjab		7 years	8.00
SN Pharma	Uttar Pradesh			Varies annually

### Notes:

- The firm caters to 82 customers across India.
- The major sales are generated from Uttar Pradesh, Rajasthan, Madhya Pradesh, and Chhattisgarh.
- Medicinum accounts for 25.00% of the total sales.

<b>Terms of credit</b>	:	Credit up to 30 days
<b>Feedback from customers</b>	:	Satisfied with the relationship
<b>Process of getting orders</b>	:	Regular orders from customers
<b>Exports</b>	:	Nil
<b>Marketing network</b>	:	<ul style="list-style-type: none"> <li>• The firm responds to the online queries raised by customers and markets its products through its website: <a href="http://www.allendalebiosciences.com">www.allendalebiosciences.com</a> and other site like <a href="http://www.indiamart.com">www.indiamart.com</a> ; <a href="http://www.tradeindia.com">www.tradeindia.com</a></li> <li>• It receives repeat orders from existing customers and relies on word-of-mouth publicity.</li> </ul>
<b>Geographical reach</b>	:	Spread across India

## Supplier profile and supply-side analysis

Supplier's / Wholesaler's name	Address	Product	Length of relationship
Logus Pharma	Haryana	Pharmaceuticals drugs	7 years
Amree Pharma			
San Houston	Punjab		

Terms of purchase	:	Credit up to 60 days
Feedback from suppliers	:	Satisfied with the relationship
Traded goods availability	:	Ample
Traded goods price volatility	:	High
Ability to pass on traded goods price increase	:	Yes
Imports	:	Nil


## Trading facilities

Employee oriented operations	:	Yes
Labour union	:	No
Employee relationships	:	Cordial
CNC machines, CAD, CAM, automation	:	Not Applicable
In-house R&D, designing facilities	:	
Availability of critical machinery and entry barrier to technology and processes used	:	
Degree of mechanisation	:	
Facility layout	:	Spacious and well organised

### Photographs of the facility



Outer view of facility 1



Inner view of facility 1



Inner view of facility 2



Inner view of facility 3

## Ownership and management

### Partners' profile

<b>Partner's name</b>	:	Arvind Kumar Sharma
<b>Age</b>	:	51 years
<b>Qualification</b>	:	Graduate
<b>Designation / responsibilities</b>	:	Manging Partner/ Overall Management
<b>Partner's experience in current business</b>	:	7 years
<b>Experience in the same line of business (including current experience)</b>	:	30 years
<b>Personal net worth</b>	:	Data sought by CRISIL, not provided by firm
<b>Partner's address</b>	:	House No. 542 Sector 12 Panchkula - 134 113, Haryana
<b>Telephone no.</b>	:	+91 7696 513 118
<b>Ownership of residence</b>	:	Owned
<b>Vehicles used</b>	:	Data sought by CRISIL, not provided by firm

<b>Partner's name</b>	:	Neeraj Giri
<b>Age</b>	:	36 years
<b>Qualification</b>	:	Graduate
<b>Designation / responsibilities</b>	:	Partner/ Overall Management
<b>Partner's experience in current business</b>	:	7 years
<b>Experience in the same line of business (including current experience)</b>	:	20 years
<b>Personal net worth</b>	:	Data sought by CRISIL, not provided by firm
<b>Partner's address</b>	:	Flat No. 18, 2 <sup>nd</sup> floor Ganesh Vihar Colony, Dhakoli, Zirakpur Mohali – 160 104, Punjab
<b>Telephone no.</b>	:	+91 8570 052 000

*Personal liquid net worth of promoters is as disclosed by management and not certified.*

## Key management personnel

No second-tier management as confirmed by the management

## Organisational structure, controls and systems

<b>Managing partner</b>	:	Arvind Kumar Sharma
<b>Constitution</b>	:	Partnership
<b>Second tier management</b>	:	Weak organisational structure
<b>Decision making powers</b>	:	Centralised with the partners
<b>Reporting system or MIS</b>	:	Yes
<b>Type of reporting system</b>	:	Computerised
<b>Frequency of MIS / reporting</b>	:	Daily
<b>Litigations against the SME</b>	:	None
<b>Litigations against the Partner</b>	:	
<b>Severity of litigations</b>	:	Not applicable
<b>Susceptibility to foreign exchange fluctuations</b>	:	
<b>Hedging against foreign exchange risks</b>	:	
<b>Susceptibility to commodity price fluctuations</b>	:	
<b>Hedging against forex risks (for export)</b>	:	
<b>Hedging against forex risks (for import)</b>	:	
<b>Hedging against commodity prices</b>	:	
<b>Asset insurance</b>	:	Adequate

## Ownership pattern

Partners' share of profits as on: March 31, 2018

Name of the partner	Relationship with managing partner	Share in capital (%)
Arvind Kumar Sharma	Self	50.00
Neeraj Giri	Business associate	50.00
	<b>Total</b>	<b>100.00</b>

## Group companies and firms

*There are no group companies and associate firms.*

## Financial profile

### Current financial performance

Performance for the period April 1 to June 30, 2018		
Net sales	Rs lakh	Data sought by CRISIL, not provided by firm
OPBDIT	Rs lakh	
Current order book	Rs lakh	
Debtors	Rs lakh	
Creditors	Rs lakh	
Capital	Rs lakh	
Total debt	Rs lakh	
Total debt- equity ratio	Times	

Projected performance in		FY19*
Net revenue	Rs lakh	500.00
PBT	Rs lakh	Data sought by CRISIL, not provided by firm
PBT margin	%	

\*The firm projects higher sales for fiscal 2019 on account of business expansion with the help of franchise and new product line of cardio diabetic division.

## Past financial performance

Estimated performance during		FY18*
Net sales	Rs lakh	380.00
PBT	Rs lakh	Data sought by CRISIL, not provided by firm
PBT margin	%	

\*As confirmed with management, net sales increased in fiscal 2018 on account of addition of 18 new franchises.

## Profit and loss account

For the year ended		2014-15	2015-16	2016-17
		Audited	Audited	Audited
Number of months		12	12	12
Net sales	Rs lakh	167.60	188.36	213.50
Operating income	Rs lakh	167.61	188.73	214.54
Cost of sales	Rs lakh	161.10	181.30	207.57
OPBDIT	Rs lakh	6.51	7.43	6.96
Interest and finance costs	Rs lakh	0.02	0.19	0.10
OPBDT	Rs lakh	6.49	7.24	6.86
Depreciation	Rs lakh	0.10	0.12	0.37
OPBT	Rs lakh	6.39	7.13	6.50
Non-operating income / (expense)	Rs lakh	0.10	0.12	0.13
PBT	Rs lakh	6.49	7.25	6.63
Extraordinary income / (expense)	Rs lakh	-	-	-
Reported PBT	Rs lakh	6.49	7.25	6.63
Provision for taxes	Rs lakh	-	-	-
Deferred tax liability / (asset)	Rs lakh	-	-	-
PAT	Rs lakh	6.49	7.25	6.63
Drawings	Rs lakh	4.11	5.65	6.63
Net cash accruals	Rs lakh	2.48	1.71	0.36

### Notes:

- Net sales increased in fiscal 2017 on account of addition of new products and investments in advertisements.
- Cost of sales for fiscal 2017, fiscal 2016 and fiscal 215 included:

For the year ended		2014-15	2015-16	2016-17
Traded good cost	Rs Lakh	139.11	156.34	177.21
Employee cost	Rs Lakh	11.88	12.43	16.78
Other expenses	Rs Lakh	9.81	11.99	12.86
Power and fuel costs	Rs Lakh	0.30	0.54	0.72
<b>Total</b>	<b>Rs Lakh</b>	<b>161.10</b>	<b>181.30</b>	<b>207.57</b>

- Interest and finance costs for fiscal 2017 comprised interest on borrowings worth Rs 0.10 lakh.
- Depreciation is charged according to the provisions of the Income Tax Act, 1961.
- Non-operating income during fiscal 2017 refers to interest on FDR.

**Balance sheet**

		31-Mar-2015	31-Mar-2016	31-Mar-2017
		Audited	Audited	Audited
<b>Liabilities</b>				
Capital	Rs lakh	47.09	57.00	43.29
Deferred tax liabilities / (assets)	Rs lakh	-	-	-
Long-term debt	Rs lakh	0.40	-	23.05
<i>of which, current portion of long-term debt</i>	<i>Rs lakh</i>	-	-	-
Short-term debt	Rs lakh	-	2.01	0.36
<i>of which, working capital borrowing from banks</i>	<i>Rs lakh</i>	-	2.01	0.36
Other liabilities and provisions	Rs lakh	42.47	56.03	61.01
<b>Total liabilities</b>	<b>Rs lakh</b>	<b>89.96</b>	<b>115.04</b>	<b>127.71</b>
<b>Assets</b>				
Net fixed assets	Rs lakh	0.42	0.69	0.86
Investments	Rs lakh	-	-	-
Inventory	Rs lakh	56.72	74.85	80.64
Receivables (total)	Rs lakh	29.95	34.81	39.13
<i>of which, receivables greater than six months</i>	<i>Rs lakh</i>	-	-	-
Cash and bank balance	Rs lakh	1.11	1.75	3.98
Other current assets	Rs lakh	1.76	2.94	3.10
<b>Total assets</b>	<b>Rs lakh</b>	<b>89.96</b>	<b>115.04</b>	<b>127.71</b>

**Notes:**

- Long-term debt as of fiscal 2017 comprises interest-free unsecured loans from partners.
- Short-term debt as of fiscal 2017 comprised overdraft facility availed from Bank of Baroda (sanctioned limit of Rs 3.00 lakh).
- Other liabilities and provisions as of fiscal 2017 comprised creditors for goods of Rs 54.16 lakh, advances from customers of Rs 4.32 lakh, salary payable of Rs 1.40 lakh, CST payable of Rs 1.04 lakh, and other current assets of Rs 0.09 lakh.
- Fixed assets as of fiscal 2017 comprised computer of Rs 0.26 lakh, furniture of Rs 0.23 lakh, mobile of Rs 0.17 lakh, air conditioner of Rs 0.11 lakh, cooler of Rs 0.08 lakh, and other fixed asset of Rs 0.01 lakh.
- Inventory as of fiscal 2017 comprised stock of traded goods.
- Other current assets as of fiscal 2017 comprised loans and advances of Rs 1.22 lakh, FDR deposit of Rs 1.00 lakh, interest accrued of Rs 0.32 lakh, and advance income tax of Rs 0.56 lakh.



## Key financial ratios

For the year ended / as at		31-Mar-2015	31-Mar-2016	31-Mar-2017
		Audited	Audited	Audited
OPBDIT margin	%	3.88	3.94	3.25
PAT margin	%	3.87	3.84	3.09
Return on capital employed	%	NM	13.96	10.70
Gross current assets	days	191	216	208
Days inventory (on COP)	days	129	151	142
Days receivable (on gross sales)	days	65	67	67
Days payable (on materials)	days	91	115	112
Current ratio	Times	2.11	1.97	2.07
Cash/TOL	%	2.59	3.02	4.72
PBDIT Interest cover	Times	More than 40.00		
Net cash accruals/Total debt	%	620.27	85.26	1.54
Debt service coverage ratio	Times	NM	25.59	51.65
Average cost of borrowing	%		15.37	0.79
Total outside liabilities/Capital	Times	0.91	1.02	1.95
Gearing - Total debt/Capital	Times	0.01	0.04	0.54
Gearing (considering promoter loans as neither debt nor equity)	Times	-	0.04	0.01

**NM:** Not meaningful

### Notes:

- Operating margin declined in fiscal 2017 mainly on account of an increase in employee cost as a % of operating income.
- Receivables and payables as of fiscal 2017, fiscal 2016, and fiscal 2015 have been stretched; reason for the same is sought by CRISIL not provided by the firm.

## Fund flow statement

For the year ended		31-Mar-2016	31-Mar-2017
<b>Sources of funds</b>			
Net cash accruals	Rs lakh	1.71	0.36
Equity infusion / Share application money	Rs lakh	8.32	-
Long-term debt borrowed (net)	Rs lakh	-	23.05
Short-term debt borrowed (net)	Rs lakh	2.01	-
Decrease in net current assets	Rs lakh	-	-
Sale of investments / fixed assets	Rs lakh	-	-
Other sources	Rs lakh	-	-
<b>Total sources of funds</b>	<b>Rs lakh</b>	<b>12.04</b>	<b>23.41</b>
<b>Uses of funds</b>			
Investment and fixed assets purchased	Rs lakh	0.39	0.53
Decrease in tangible net worth	Rs lakh	-	13.70
Long-term debt repaid (net)	Rs lakh	0.40	-
Short-term debt repaid (net)	Rs lakh	-	1.65
Increase in net current assets	Rs lakh	11.25	7.53
Other uses	Rs lakh	-	-
<b>Total uses of funds</b>	<b>Rs lakh</b>	<b>12.04</b>	<b>23.41</b>

### Notes:

- The decrease in tangible net worth in fiscal 2017 was on account of withdrawal of capital in excess of profits.
- Increase in net current assets in fiscal 2016 and fiscal 2017 was on account of increase in inventory, receivables, and cash and bank balance.

## Contingent liabilities

**Contingent liabilities as on fiscal 2017:** Nil

## Auditors


A.K. Sood & Associates (Membership No. 507583)  
 Gaurav Sood, Chartered Accountants  
 SCO 126-127, 2<sup>nd</sup> Floor, Sector 8-C  
 Chandigarh – 160 018, Chandigarh

### Auditors' comments and observations in their audit report for fiscal 2017, fiscal 2016, and fiscal 2015:

No adverse comments and observations

**Change in auditors, if any:** None

## Graphs



## Banking facilities

Name and location of the bank	Length of relationship	Facilities availed	Type of facility	Loan amount	Rate (%)
Bank of Baroda	7 years	Bank overdraft	Fund-based limit	Rs 3.00 lakh*	Data sought by CRISIL, not provided by firm
HDFC Bank Limited		Current account	Not applicable		

\*Sanction limit as on March 31, 2017

**Feedback:** Account performance is satisfactory

## Site visit

<b>Address of the site visited</b>	:	Plot No. 363, 2nd Floor Industrial Area, Phase 2 Panchkula – 134 113, Haryana
<b>Date of site visit</b>	:	August 30, 2018
<b>Name of BA representative</b>	:	Sonu Tagore
<b>Name of client's representative</b>	:	Neeraj Giri
<b>Designation of client's representative</b>	:	Partner/ Overall Management
<b>Mobile No of client's representative</b>	:	+91 8570 052 000
<b>Email of client's representative</b>	:	<a href="mailto:neerajgiri@voizmel.com">neerajgiri@voizmel.com</a>
<b>No. of floors occupied</b>	:	One Floor
<b>Size of premises</b>	:	3,320 square feet
<b>Number of employees at the location</b>	:	9 (at the time of visit)
<b>Child labour at the site</b>	:	No
<b>Locality</b>	:	Industrial
<b>Location area</b>	:	Urban
<b>Site location</b>	:	Side lanes
<b>Site used as</b>	:	<ul style="list-style-type: none"> <li>• Administrative office</li> <li>• Regional office</li> <li>• Sales office</li> <li>• Factory</li> <li>• Warehouse</li> </ul>
<b>Site layout</b>	:	Spacious and Well Organized
<b>Space around the building / structure</b>	:	<ul style="list-style-type: none"> <li>• Front porch</li> <li>• Side space</li> </ul>
<b>State of infrastructure</b>	:	<ul style="list-style-type: none"> <li>• Power: Stable</li> <li>• Backup power: Available</li> <li>• Water: Available</li> <li>• Labour unions: Do Not Exit</li> <li>• Transportation: Easily available</li> <li>• Overall infrastructure: Satisfactory</li> </ul>
<b>Electricity units consumed in the past three months</b>	:	<ul style="list-style-type: none"> <li>• July 2018: 823 units</li> <li>• August 2018: 879 units</li> <li>• September 2018: 798 units</li> </ul>
<b>Building structure</b>	:	Permanent structure
<b>Ownership of premises</b>	:	Rented
<b>Sharing premises with group concerns</b>	:	No
<b>Facilities available at the site</b>	:	<ul style="list-style-type: none"> <li>• Telephone</li> <li>• Generator</li> <li>• Internet</li> <li>• Fax</li> <li>• Name or sign boards</li> <li>• Fire extinguisher</li> <li>• Drinking water</li> <li>• Transport arrangement</li> <li>• Boundary wall</li> <li>• Drainage and sewerage</li> <li>• Pantry and Canteen</li> </ul>
<b>Installed capacity (annual)</b>	:	Not applicable
<b>Utilized Capacity (annual)</b>	:	
<b>Name of the Raw material being used</b>	:	
<b>Source of raw material</b>	:	

<b>Environmental clearance (if required)</b>	:	Not obtained
<b>Any other site-specific observations</b>	:	None

**THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK**





## CRISIL SME Ratings Contacts

### Head Office

#### CRISIL House

Central Avenue  
Hiranandani Business Park  
Powai, Mumbai 400 076  
Tel: +91 22 3342 3000  
Fax: +91 22 3342 3001

**Contact:** Mr. Rahul Prasad  
**E-mail:** [rahul.prasad@crisil.com](mailto:rahul.prasad@crisil.com)

### CRISIL Branch Offices

#### Ahmedabad

Unit No. 706, 7th Floor,  
Venus Atlantis, Prahladnagar,  
Satellite, Ahmedabad - 380015  
INDIA  
Phone : +91 79 4024 4500  
Fax : +91 79 4024 4520

**Contact:** Mr. Pranav Ranjan  
**E-mail:** [pranav.ranjan@crisil.com](mailto:pranav.ranjan@crisil.com)

#### Bengaluru

W - 101, 1st floor, Sunrise  
Chambers, 22, Ulsoor Road,  
Bengaluru - 560042  
INDIA  
Phone: +91 80 4244 5399  
Fax: +91 80 4244 5300

**Contact:** Mr. Bharath BC  
**E-mail:** [bharath.bc@crisil.com](mailto:bharath.bc@crisil.com)

#### Chennai

Thapar House, Mezzanine Floor,  
No. 37 Montieth Road,  
Egmore,  
Chennai - 600 008  
INDIA  
Phone: +91 44 2854 6205 - 06 /  
91-44-2854 6093  
Fax: +91 44 2854 7531

**Contact:**  
Mr. Surendran Jayasankaran  
**E-mail:** [surendran.jayasankaran@crisil.com](mailto:surendran.jayasankaran@crisil.com)

#### Gurgaon

CRISIL House  
Plot No. 46, Sector 44,  
Opp PF Office, Gurgaon,  
Haryana,  
INDIA  
Phone: +91 0124 672 2000

**Contact:**  
Mr Kunal Raman  
**E-mail:** [kunal.raman@crisil.com](mailto:kunal.raman@crisil.com)

#### Hyderabad

Uma Chambers, 3rd Floor,  
Plot No. 9&10, Nagarjuna Hills,  
Near Punjagutta Cross Road  
Hyderabad - 500 082  
INDIA  
Phone: +91 40 2335 8103 - 05  
Fax: +91 40 2335 7507

**Contact:** Mr. Bharath BC  
**E-mail:** [bharath.bc@crisil.com](mailto:bharath.bc@crisil.com)

#### Kolkata

Convergence Building  
3rd Floor, D2/2, EPGP Block  
Sector V, Salt Lake City,  
Kolkata - 700 091  
INDIA  
Phone: +91 33 4011 8200  
Fax: +91 33 4011 8250

**Contact:** Ms. Sona Singh  
**E-mail:** [sona.singh@crisil.com](mailto:sona.singh@crisil.com)  
Mr. Rashid Raza Jafri  
**E-mail:** [rashid.syed@crisil.com](mailto:rashid.syed@crisil.com)

#### Pune

1187/17, Ghole Road  
Shivaji Nagar  
Pune 411 005  
Tel: +91 20 4018 1900  
Fax: +91 20 4018 1930

**Contact:**  
Mr. Rahul Prasad  
**E-mail:** [rahul.prasad@crisil.com](mailto:rahul.prasad@crisil.com)  
Ms Renu Chauhan  
**Email:** [renu.chauhan@crisil.com](mailto:renu.chauhan@crisil.com)

### Other Contact Points

#### Coimbatore

CRISIL Limited  
New No. 750-7, Old No. 1055-6,  
1st Floor Gowtham Centre.  
Opposite Nilgiris, Avinashi Road  
Coimbatore – 641 018  
Tel: +91 422 224 4559

**Contact:** Mr. Balakrishnan B  
**E-mail:** [balakrishnan.b@crisil.com](mailto:balakrishnan.b@crisil.com)

#### Mohali/ Chandigarh

CRISIL Limited  
SCF-29, Top Floor, Phase -5  
Mohali- 160055  
Tel: +91 172 502 7196 / 97

**Contact:**  
Mr. Tejinder Pal Singh  
**E-mail:** [tejinderpal.singh@crisil.com](mailto:tejinderpal.singh@crisil.com)  
Mr. Dharmesh Handa  
**E-mail:** [dharmesh.handa@crisil.com](mailto:dharmesh.handa@crisil.com)

#### New Delhi

S 205, Dev Tower,  
Samachar Market,  
Mayur Vihar, Ext Phase I,  
New Delhi – 110091

**Contact:**  
Mr Kunal Raman  
**E-mail:** [kunal.raman@crisil.com](mailto:kunal.raman@crisil.com)  
Mr. Amit Swarnkar  
**E-mail:** [amit.swarnkar@crisil.com](mailto:amit.swarnkar@crisil.com)

### **About CRISIL Limited**

CRISIL is a global, agile and innovative analytics company driven by its mission of making markets function better. We are India's foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers.

We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

### **About CRISIL Ratings**

CRISIL Ratings is part of CRISIL Limited ("CRISIL"). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI"). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 95,000 MSMEs have been rated by us.

### **CRISIL Privacy Notice**

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the "Company") you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit [www.crisil.com/privacy](http://www.crisil.com/privacy). You can view the Company's Customer Privacy at <https://www.spglobal.com/privacy>

**Last updated: April 2016**